Dan Pollyea, MD, Discusses Venetoclax For Patients With AML Harboring IDH Mutations

News
Video

Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations

In an interview with CancerNetwork®, Daniel A. Pollyea, MD of the University of Colorado Cancer Center, discussed the rationale behind a study of venetoclax (Venclexta) and azacitidine (Vidaza) for patients with acute myeloid leukemia with IDH mutations.

Transcription:

What this study explores is the particular subset of patients who have IDH mutation[s]. We’ve known from the very beginning of the clinical experience with venetoclax that IDH patients respond even better than the patients who don’t have an IDH mutation. So this study really is the largest look at that, with an opportunity to look at several 100 patients with IDH mutations and what their outcomes were with venetoclax-based regimens, and then look at the placebo group, as well, that didn’t receive venetoclax. So, I think this helps answer a lot of questions that folks have had regarding to what degree this impacts outcomes, and it’s a pretty large degree of response.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content